VIM and lip and oral cavity carcinoma: These findings fill a gap in our understanding of oncogenesis and metastasis of oral cancers caused by KSHV and HPV31, revealing that vimentin may serve as a potential therapeutic molecular target for KSHV- and HPV-associated oral cancer.